Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
May 20, 2019
Distillery Therapeutics
Analog of pleuromutilin identified for multiple cancers
...compared with vehicle. Next steps could include testing ferroptocide in mouse models of other cancers.
Vanquish Oncology Inc.
...
Read More
BioCentury
|
May 14, 2015
Distillery Therapeutics
Therapeutics: Procaspase-3; caspase-3 (CASP3; CPP32)
...AUCs and oral availability. Next steps include testing the compounds in animal models of cancer.
Vanquish Oncology Inc.
...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
May 20, 2019
Distillery Therapeutics
Analog of pleuromutilin identified for multiple cancers
...compared with vehicle. Next steps could include testing ferroptocide in mouse models of other cancers.
Vanquish Oncology Inc.
...
Read More
BioCentury
|
May 14, 2015
Distillery Therapeutics
Therapeutics: Procaspase-3; caspase-3 (CASP3; CPP32)
...AUCs and oral availability. Next steps include testing the compounds in animal models of cancer.
Vanquish Oncology Inc.
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page